Endometriosis: Seven-Market Drug Forecast and Market Analysis to 2034

List of Tables

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Endometriosis market through 2034.

GlobalData estimates the 2024 sales for the endometriosis market at approximately $938.0 million across the 7MM, encompassing the US, the 5EU, and Japan. By 2034, GlobalData expects the overall market to grow at a compound annual growth rate (CAGR) of 10.3% to reach sales of $2.5 billion over the 10-year period. The US market will grow fastest, with a 13.2% CAGR, compared to a decline of 0.7% in the 5EU and growth of 1.0% in Japan. At the end of 2034, the US will contribute approximately 88.4% of global sales. The higher sales in the US relative to the other two regions can be attributed to the greater diagnosed prevalence of endometriosis in the US and the higher price of drugs in the US compared to other global markets.

Major drivers of the endometriosis market during the forecast period will include -

The launch of Kissei Pharmaceutical's Yselty (linzagolix), which is currently marketed in the in the US and Japan
The launch of Hope Medicine's HMI-115 in the US and Fuji Pharma's Alyssa (drospirenone + estetrol) in Japan
Continual improvements with disease awareness, leading to an increase in diagnoses
Improvements in non-invasive diagnostic methods, such as the utilization of biomarkers, which should further increase the number of early diagnoses

Major barriers to the growth of the endometriosis market during the forecast period are as follows -

The endometriosis market boasts many off-label medications and is still highly genericized, presenting a stiff barrier for novel therapy entrants.
The shrinking female population ages 12-54 years in the 5EU and Japan will dampen the extent of growth in diagnosed endometriosis cases.

Scope

Overview of endometriosis, including epidemiology, symptoms, diagnosis, and disease management.
Annualized endometriosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the endometriosis therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for endometriosis treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM endometriosis therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM endometriosis therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC316PIDR-7M

1 Endometriosis: Executive Summary

1.1 The endometriosis market will exhibit considerable growth from 2024 to 2034
1.2 Key players will continue their competitive position in the endometriosis market over the forecast period
1.3 Current therapies leave significant unmet needs in the endometriosis market
1.4 Late-stage pipeline drugs entering the endometriosis market are poised to drive growth
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.5 Epidemiological forecast for endometriosis (2024-34)
4.6 Discussion

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Non-invasive diagnostics
7.3 Disease awareness and education of medical professionals
7.4 More effective drugs with long-term safety and tolerability
7.5 Non-hormonal therapies
7.6 Better understanding of the disease etiology and pathophysiology

8 R&D Strategies

8.1 Overview
8.2 Clinical trials design

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors
About GlobalData
Contact Us

Product Code: GDHC316PIDR-7M

List of Table

List of Tables

Table 1: Endometriosis: key metrics in the 7MM
Table 2: Role of the different theories in the pathogenesis of endometriosis
Table 3: Classifications of endometriosis
Table 4: Risk factors and comorbidities for endometriosis
Table 5: The most used guidelines by country
Table 6: Top 10 deals by value, 2020-25
Table 7: Endometriosis market - global (7MM) drivers and barriers, 2024-34
Table 8: Key events impacting sales for endometriosis in the US, 2024-34
Table 9: Endometriosis market - drivers and barriers in the US, 2024-34
Table 10: Key events impacting sales for endometriosis in the 5EU, 2024-34
Table 11: Endometriosis market - drivers and barriers in the 5EU, 2024-34
Table 12: Key events impacting sales for endometriosis in Japan, 2024-34
Table 13: Endometriosis market - drivers and barriers in Japan, 2024-34
Table 14: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for endometriosis in 2024 and 2034
Figure 2: Analysis of the company portfolio gap in endometriosis during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of endometriosis during the forecast period
Figure 4: Roles of estrogen receptor a and estrogen receptor B in normal endometrium and endometrial lesions
Figure 5: Endometrial lesions of varying depth
Figure 6: Sources of estradiol in endometriosis tissue and targets of the current medical therapy
Figure 7: 7MM, diagnosed incidence of endometriosis (cases per 100,000 population), women, ages 12-54 years, 2024
Figure 8: 7MM, diagnosed prevalence of endometriosis (%), women, ages 12-54 years, 2024
Figure 9: 7MM, sources used and not used to forecast the diagnosed incident cases of endometriosis
Figure 10: MM, sources used and not used to forecast the diagnosed prevalent cases of endometriosis
Figure 11: 7MM, sources used to forecast the laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis
Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by ASRM stage
Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by phenotype
Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by comorbidities
Figure 15: 7MM, diagnosed incident cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 16: 7MM, diagnosed incident cases of endometriosis by age, N, women, 2024
Figure 17: 7MM, laparoscopy confirmation status for the diagnosed incident cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 18: 7MM, diagnosed prevalent cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 19: 7MM, diagnosed prevalent cases of endometriosis by age, N, women, 2024
Figure 20: 7MM, laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 21: 7MM, diagnosed prevalent cases of endometriosis by ASRM stage, N, women, ages 12-54 years, 2024
Figure 22: 7MM, diagnosed prevalent cases of endometriosis by phenotype, N, women, ages 12-54 years, 2024
Figure 23: 7MM, diagnosed prevalent cases of endometriosis by comorbidities, N, women ages 12-54 years, 2024
Figure 23: Sample endometriosis treatment algorithm
Figure 25: Unmet needs and opportunities in endometriosis
Figure 26: Overview of the development pipeline in endometriosis
Figure 27: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for endometriosis in the 7MM during the forecast period
Figure 28: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for endometriosis in the 7MM during the forecast period
Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against the GnRH antagonist, Orilissa
Figure 30: Competitive assessment of the marketed and pipeline drugs benchmarked against the hormonal contraceptives
Figure 31: Competitive assessment of the marketed and pipeline drugs benchmarked against the subcutaneous agent, Zoladex
Figure 32: Analysis of the company portfolio gap in endometriosis during the forecast period
Figure 33: Global (7MM) sales forecast by country for endometriosis in 2024 and 2034
Figure 34: Sales forecast by class for endometriosis in the US in 2024 and 2034
Figure 35: Sales forecast by class for endometriosis in the 5EU in 2024 and 2034
Figure 36: Sales forecast by class for endometriosis in Japan in 2024 and 2034

Endometriosis: Seven-Market Drug Forecast and Market Analysis to 2034

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Endometriosis: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures